Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy

Mary Elizabeth Cox¹
Jennifer Rowell¹
Leonor Corsino¹
Jennifer B Green¹,²

¹Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Durham, NC, USA; ²Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, USA

Abstract: Although glycemic control is an important and effective way to prevent and minimize the worsening of diabetes-related complications, type 2 diabetes is a progressive disease which often proves difficult to manage. Most affected patients will eventually require therapy with multiple medications in order to reach appropriate glycemic targets. The dipeptidyl peptidase-4 (DPP-4) inhibitors constitute a relatively new class of oral medications for the treatment of type 2 diabetes, which has become widely incorporated into clinical practice. This review summarizes the available data on the efficacy, safety, and tolerability of these medications.

Keywords: type 2 diabetes, pharmacotherapy, DPP-4 inhibitor, sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin

Introduction

Although glycemic control is an important and effective way to prevent and minimize the worsening of diabetes-related complications, type 2 diabetes is a progressive disease which often proves difficult to manage.¹⁻³ Most affected patients will eventually require therapy with multiple medications in order to reach appropriate glycemic targets.⁴ The number of new glucose-lowering therapies has increased dramatically over the past decade, and prospective agents continue to be developed as new physiologic targets are identified. There are a number of important considerations when choosing antihyperglycemic therapies for treatment of patients with type 2 diabetes. These include the glucose-lowering potency of the medication; the presence of co-morbid conditions in the patient being treated; possible adverse side effects of the drugs being used; the risk of hypoglycemia with given classes or combinations of agents; and the potential for weight gain associated with various drug classes. Additional considerations include the impact of therapy on cardiovascular health and potential for beta cell preservation, as well as concern for carcinogenic or mitogenic properties of existing therapies.

The dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs represents one of the newest groups available for diabetes treatment. Two DPP-4 inhibitors are currently available in the United States: sitagliptin and saxagliptin. Vildagliptin is a third DPP-4 inhibitor available in Europe and many other countries, although approval in the US is still pending. Alogliptin and linagliptin are among the DPP-4 inhibitors still under development. These agents have an attractive mechanism of action, described in detail in the following sections, which complements those of many existing therapies. These agents have consistently been found to lower blood glucose and hemoglobin A₁c (HbA₁c).
levels, and the safety and tolerability of these medications have generally been good.

Although the potential for clinical use of DPP-4 inhibitors is extensive, the use of this drug class has not been formally recommended by all expert panels. In early 2009, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) released a consensus statement for management of type 2 diabetes, including an updated algorithm for medication management. This algorithm focuses on lifestyle modifications and use of well-validated core therapies. Other than exenatide, which is listed as a “less-well-validated therapy,” incretin-based therapies are not included. Reasons given for the exclusion of the DPP-4 inhibitor class from the algorithm are that these agents are no more effective in lowering glucose than is insulin; that the DPP-4 inhibitors have unestablished long-term safety; and that they are more expensive than insulin. However, data continue to accrue for these agents, and there may be selected cases in which use of these medications would be preferable to more traditionally prescribed therapies. This review will summarize the existing information on incretin physiology, as well as the efficacy, safety, and tolerability of the DPP-4 inhibitors.

**Physiology**

**Incretin hormones and the incretin effect**

Incretins are a group of insulinotropic hormones that are secreted by the gut in response to food intake. The class of hormones was first discovered in 1902, and in 1964 the incretin effect was described. The incretin effect refers to the more robust increase in insulin secretion in response to orally ingested glucose, as compared to the response elicited by glucose given intravenously. In the seminal trials, this effect was maintained despite the presence of higher blood glucose levels during the intravenous infusion. Subsequently, more details have emerged about the two hormones largely responsible for the incretin effect: glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

GLP-1 is the most potent known incretin. The level of GLP-1 rises quickly in response to food ingestion; this has direct effects on pancreatic endocrine function, including both insulin release from the beta cells and suppression of glucagon release from the alpha cells. There is some limited evidence that GLP-1 also acts at peripheral tissues to improve insulin utilization. Other effects of GLP-1 include slowed gastric emptying and the promotion of satiety at the level of the central nervous system. GIP, the other well-described but perhaps less well understood incretin hormone, promotes similar food and glucose-dependent insulin release. However, as opposed to GLP-1, it may exert a stimulatory effect on glucagon release. An important feature of both incretin hormones is that their activity is glucose-dependent: glucolowering activity ceases when blood glucose levels fall below 65 mg/dL. Furthermore, in animal models, both GLP-1 and GIP are suspected to have a stimulatory effect upon the growth, proliferation, and differentiation of beta cells. The half-lives of GLP-1 and GIP are only a few minutes long, as they are rapidly degraded to largely inactive metabolites by DPP-4.

**Incretin hormones and DPP-4 in type 2 diabetes**

In individuals with type 2 diabetes, the incretin effect appears to be blunted. This blunting has been attributed to 2 factors: GLP-1 levels are lower and GIP exerts a lesser physiologic effect than seen in normoglycemic individuals. Responsiveness to GLP-1 is generally preserved; infusion of GLP-1 to individuals with diabetes has been shown to lower both postprandial and fasting blood glucose levels. Conversely, there appear to be relatively normal levels of GIP in persons with type 2 diabetes, but their physiologic response to GIP is diminished. Whether or not abnormalities in DPP-4 levels or degradative activity exist in patients with diabetes is still unclear.

The administration of DPP-4 inhibitors to individuals with type 2 diabetes has been shown to raise levels of endogenous GLP-1 and GIP, which in turn results in a glucose-appropriate increase in insulin secretion and suppression of glucagon release. In patients with type 2 diabetes, administration of DPP-4 inhibitors has been shown to improve markers of insulin processing, including homeostasis model assessment of beta cell function (HOMA-β) and the proinsulin:insulin ratio. Furthermore, there are animal data to suggest that pancreatic beta cell mass may be preserved; beta cells may even be stimulated to grow and proliferate in the presence of these agents. However, no comparable anatomic data in humans are available.

**Other roles of DPP-4 and homologous enzymes**

DPP-4 circulates in soluble form in the plasma and is responsible for the inactivation of a number of hormones and peptides. In addition to the incretin hormones, these include substance P, whose fragment byproduct is important for sensory nerve transmission, and chemokines associated with interferon induction, macrophage signaling, eosinophil recruitment, and inhibition of mononuclear HIV-1 infection. DPP-4 inhibitors may also have a role in neuropeptide...
signaling by prolonging the action of neuropeptide Y and growth hormone-releasing hormone.21

In addition to the soluble form, there is a membrane-bound form of DPP-4, also called CD26, with an extracellular enzymatic domain and an intracellular domain involved with signal transduction cascades. Membrane-bound DPP-4 is found in epithelial cells, leukocytes, and other human tissues, including mammary glands, uterus, placenta, adrenal glands, exocrine pancreas, lymph nodes, gastrointestinal tract, and kidney.18,19 It has multiple roles, with apparent involvement in T-lymphocyte activation.20 DPP-4 levels have been found to be reduced in association with chronic rhinosinusitis and increased in association with multiple sclerosis and Graves’ disease.21 Abnormal expression of both the soluble and membrane-bound forms has been associated with prostate cancer, melanoma, rheumatic diseases, HIV, and hepatitis C infection.19 In addition, T-cell hematologic malignancies, including lymphomas and lymphoproliferative disorders, have been associated with altered expression of DPP-4.19,20 Furthermore, rat transplantation studies indicate that DPP-4 inhibition may delay cardiac allograft rejection.19 It is as yet unclear to what extent this membrane-bound enzyme can be affected by pharmacological DPP-4 inhibition in vivo in humans.19,22,23

DPP-4 shares homology with other enzymes through a common enzymatic cleaving mechanism.18,22 These include DPP-7 (also called quiescent cell proline dipeptidase and DPP-2), DPP-8, DPP-9, fibroblast activation protein (FAP), attractin, and DPP-4β.22 Direct inhibition of DPP-7, DPP-8, and DPP-9 has been investigated in animal models. Administration of DPP-8 and DPP-9 inhibitors was associated with alopecia, thrombocytopenia, splenomegaly, reticulopenia, and gastrointestinal toxicity, while administration of DPP-7 inhibitors was associated with reduced reticulocyte count.18,22 Of the commercially available DPP-4 inhibitors sitagliptin, saxagliptin, and vildagliptin, interactions have been seen in vitro with only DPP-8 and DPP-9.24 However, no clear indication of DPP-8/DPP-9-related adverse events has been observed in clinical trials.24 It will be important for future development to focus on drugs that are specific inhibitors of DPP-4, and, if possible, of only the soluble form. Furthermore, investigations need to be conducted to examine effects of existing DPP-4 inhibitors in patients who are at risk for or who are affected by infectious and inflammatory conditions.

Pharmacokinetics of available agents
The mechanism of action of the various DPP-4 inhibitors appears to be similar. All of the named therapies inhibit DPP-4 activity by greater than 80%, which is the level of inhibition at which maximal glucose lowering is seen.25 Vildagliptin is metabolized at the kidney prior to excretion, saxagliptin is partially metabolized by the liver, and sitagliptin is largely unmetabolized prior to excretion by the kidney.26-29

Sitagliptin was the first commercially available DPP-4 inhibitor, and the agent with which there is to date the most clinical experience. Sitagliptin is dosed at 100 mg daily; in healthy patients, this dose inhibits DPP-4 activity by 80% over 24 hours. Sitagliptin is approved for use in patients with renal insufficiency, although a dose reduction is necessary in patients with moderate or severe renal dysfunction. Sitagliptin should be reduced to 50 mg daily for creatinine clearance 30 to <50 mL/min and to 25 mg daily for creatinine clearance <30 mL/min.30,31 The medication may be taken once daily with or without food. Sitagliptin does not induce the CYP3A4 system and is not expected to interact with drugs metabolized through this pathway. Adverse drug–drug interactions have not been seen in studies evaluating combinations with glyburide, metformin, rosiglitazone, and pioglitazone.32-35 Outcomes data from trials of sitagliptin used in conjunction with insulin are not yet available. Drug metabolism does not differ between obese and lean subjects.27 Sitagliptin has been studied in patients with diverse ethnic backgrounds, including Japanese, Korean, Chinese, and Indian subjects, with apparent similar activity in all of these groups.36,37

Vildagliptin is prescribed at dosages of 50 mg once or twice daily; absorption is not affected by food intake.38 It has not been studied in patients with renal dysfunction, but renal clearance of the drug was noted to be reduced in elderly subjects.39 Similar to sitagliptin, it is excreted predominantly in the urine, although only 22% remains unmetabolized at the time of excretion. Metabolism occurs at the level of the kidney and not through the CYP3A4 system, thus vildagliptin does not affect this enzymatic system.28 Coadministration of metformin and vildagliptin in patients with type 2 diabetes resulted in small and clinically insignificant effects on the pharmacokinetics of each drug; however, neither drug should require a dose adjustment in the presence of the other.40 Significant drug interactions have not been seen in studies with glyburide, pioglitazone, ramipril, amlodipine, valsartan, simvastatin, digoxin, or warfarin.41-45 Drug metabolism does not appear to be affected by gender or body mass index (BMI).46 The pharmacokinetics of vildagliptin do not appear to differ significantly in the Chinese population compared to other ethnic groups studied.46
Saxagliptin is the most recently approved DPP-4 inhibitor. It is currently available as a once daily oral medication, usually dosed at 5 mg daily; 45 Saxagliptin is rapidly and extensively absorbed after oral dosing and can be taken with or without food. Saxagliptin has an active metabolite, M2, which is also cleared primarily by the kidneys. Saxagliptin is metabolized in part by the CYP3A4/5 enzymes, and its concomitant use with strong CYP3A4/5 inhibitors significantly increases the drug concentration. If such a drug combination is necessary, the saxagliptin dose should be decreased to 2.5 mg daily. In patients with renal dysfunction evidenced by a creatinine clearance of $\leq 50$ mL/min, dose reduction to 2.5 mg daily is also recommended. 29

Alogliptin and linagliptin are DPP-4 inhibitors in development but not yet commercially available. In brief, alogliptin is also a rapidly absorbed oral medication, with an activity half-life of 12 to 21 hours and predominantly renal excretion. At the doses likely to be recommended for clinical use, inhibition of DPP-4 is greater than 90%. 48 Linagliptin given at doses of 5 and 10 mg daily to men with type 2 diabetes resulted in DPP-4 inhibition of greater than 90%. It appears to have a long terminal half-life compared to the other agents – around 130 hours – leading to sustained inhibition of DPP-4 activity. Excretion of linagliptin is predominantly renal. 49

None of the DPP-4 inhibitors have been studied in pregnant or lactating women, thus their use in these populations cannot be recommended.

**Efficacy**

**Glucose-lowering effects (Table 1)**

DPP-4 inhibitors have been vigorously examined in randomized controlled trials and have generally been found to lower HbA₁c levels significantly more than placebo. Sitagliptin and vildagliptin are the most studied, and two major meta-analyses have been performed on available trial data. 50, 51 Amori et al determined that the overall weighted mean placebo-subtracted HbA₁c reduction for these two drugs is 0.74%. 50 In their 2009 meta-analysis, Monami et al examined both published and unpublished data of sitagliptin and vildagliptin efficacy. The average placebo-subtracted HbA₁c reductions were 0.70% and 0.68% respectively. Similar HbA₁c reductions with these two drugs have been seen in trials of both monotherapy and add-on therapy. Sitagliptin has been examined in combination with metformin, glimepiride, metformin plus glimepiride, and pioglitazone. 32, 52-55 Noninferiority comparisons of glucose lowering have found that sitagliptin therapy is noninferior to glipizide or rosiglitazone but somewhat less effective than full-dose metformin or exenatide. 54, 56-58 Vildagliptin has been examined in combination with metformin, glimepiride, pioglitazone, and insulin. 59-63 Noninferiority comparisons have concluded that vildagliptin is similar in efficacy to rosiglitazone, pioglitazone, or acarbose, but is not as effective as metformin. 64-69

Two studies of sitagliptin monotherapy and 1 study of vildagliptin monotherapy reported substantially larger reductions in HbA₁c for patients with high baseline HbA₁c values. Raz et al reported a trial of sitagliptin 100 mg daily, which resulted in a mean placebo-subtracted HbA₁c reduction of 1.2% for the group with baseline HbA₁c $> 9\%$ as compared to reductions of 0.44% for baseline HbA₁c $< 8\%$ and 0.6% for baseline 8% to 9%. 16 Aschner et al reported similar mean placebo-subtracted reductions: 0.57%, 0.81%, and 1.52% for baseline HbA₁c of $< 8\%$, 8% to 9%, and $> 9\%$, respectively. 70 Pratley et al reported a trial of vildagliptin 25 mg twice daily resulting in a mean placebo-subtracted HbA₁c reduction of 0.6% in patients with baseline HbA₁c $< 8\%$ and a reduction of 1.2% in those with baseline of 8% to 9.5%. 71 Interestingly, upon meta-analysis, there was a nonsignificant trend toward a greater reduction of HbA₁c in trials enrolling patients with a mean baseline HbA₁c less than 8%. 51 A clear explanation for this discrepancy is not currently available.

Five efficacy trials for saxagliptin have been published, with mean placebo-subtracted HbA₁c reductions ranging from 0.45% to 0.83%. 47, 72-74 However, Jadzinsky et al recently reported a large, 24-week randomized, controlled trial of saxagliptin 10 mg versus a combination of saxagliptin and metformin; a 1.7% mean placebo-subtracted HbA₁c reduction was seen in the saxagliptin monotherapy group. This trial had a higher mean baseline HbA₁c level, 9.5%, compared to other saxagliptin monotherapy trials, where mean baseline HbA₁c levels otherwise ranged from 7.8% to 8.4%. 47, 72-75 Rosenstock et al reported a similarly large reduction from baseline of 1.87% in a small open-label cohort with a mean baseline HbA₁c of 10.7%. 67 Efficacy of saxagliptin was maintained in two 24-week combination trials, one each with metformin and glyburide. 74, 75

Three efficacy trials have been reported for alogliptin, which have shown mean placebo-subtracted HbA₁c reductions ranging from 0.39% to 0.58%. Monotherapy data are not available, but combinations of alogliptin with metformin, glyburide, and insulin appear to yield similar glucose-lowering effects. 76-78

Efficacy data for linagliptin are pending; currently 2 trials are recruiting participants. The first will examine
Table 1 Dipeptidyl peptidase inhibitors efficacy trials summary

<table>
<thead>
<tr>
<th>Study author</th>
<th>Number patients</th>
<th>Dose</th>
<th>Compared to</th>
<th>Add-on to</th>
<th>Trial duration</th>
<th>Baseline mean hemoglobin A1c</th>
<th>Mean hemoglobin A1c reduction*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin</td>
<td>Raz 16</td>
<td>521</td>
<td>100 or 200 mg daily</td>
<td>Placebo</td>
<td>Diet/exercise</td>
<td>18 weeks</td>
<td>8.1%</td>
</tr>
<tr>
<td></td>
<td>Aschner 30</td>
<td>741</td>
<td>100 or 200 mg daily</td>
<td>Placebo</td>
<td>Diet/exercise</td>
<td>24 weeks</td>
<td>8.0%</td>
</tr>
<tr>
<td></td>
<td>Scott 52</td>
<td>743</td>
<td>5, 12.5, 25, 50 mg twice daily</td>
<td>Placebo</td>
<td>Diet/exercise</td>
<td>12 weeks</td>
<td>7.9%</td>
</tr>
<tr>
<td></td>
<td>Hanefield 81</td>
<td>555</td>
<td>25, 50, 100 mg daily, 50 mg twice daily</td>
<td>Placebo</td>
<td>Diet/exercise</td>
<td>12 weeks</td>
<td>7.6%–7.8%</td>
</tr>
<tr>
<td></td>
<td>Raz 22</td>
<td>190</td>
<td>100 mg daily</td>
<td>Placebo</td>
<td>Metformin</td>
<td>30 weeks</td>
<td>9.2%</td>
</tr>
<tr>
<td></td>
<td>Charbonne 93</td>
<td>701</td>
<td>100 mg daily</td>
<td>Placebo</td>
<td>Metformin</td>
<td>24 weeks</td>
<td>8%</td>
</tr>
<tr>
<td></td>
<td>Scott 54</td>
<td>273</td>
<td>100 mg daily</td>
<td>Placebo</td>
<td>Metformin</td>
<td>18 weeks</td>
<td>7.7%</td>
</tr>
<tr>
<td></td>
<td>Hermansen 55</td>
<td>441</td>
<td>100 mg daily</td>
<td>Placebo</td>
<td>Glimeperide or glimeperide + metformin</td>
<td>24 weeks</td>
<td>8.3%</td>
</tr>
<tr>
<td></td>
<td>Rosenstock 22</td>
<td>353</td>
<td>100 mg daily</td>
<td>Placebo</td>
<td>Pioglitazone</td>
<td>24 weeks</td>
<td>8.0%</td>
</tr>
<tr>
<td></td>
<td>Goldstein 56</td>
<td>1091</td>
<td>100 mg daily</td>
<td>Placebo or metformin or sitagliptin/metformin combination</td>
<td>Diet/exercise</td>
<td>24 weeks</td>
<td>8.8%</td>
</tr>
<tr>
<td></td>
<td>Nauck 27</td>
<td>1172</td>
<td>100 mg daily</td>
<td>Glipizide 5 to 20 mg daily</td>
<td>Metformin</td>
<td>52 weeks</td>
<td>7.5%</td>
</tr>
<tr>
<td></td>
<td>DeFronzo 98</td>
<td>61</td>
<td>100 mg daily</td>
<td>Exenatide 10 µg twice daily</td>
<td>Metformin</td>
<td>2 weeks, with 2-week cross-over</td>
<td>8.5%</td>
</tr>
<tr>
<td></td>
<td>Scott 24</td>
<td>273</td>
<td>100 mg daily</td>
<td>Rosiglitazone 8 mg</td>
<td>Metformin</td>
<td>18 weeks</td>
<td>7.7%</td>
</tr>
</tbody>
</table>

Vildagliptin

| Pratley 71  | 98   | 25 mg twice daily | Placebo | Diet/exercise | 12 weeks | 8.0% | 0.6% |

(Continued)
<table>
<thead>
<tr>
<th>Study author</th>
<th>Number patients</th>
<th>Dose</th>
<th>Compared to</th>
<th>Add-on to</th>
<th>Trial duration</th>
<th>Baseline mean hemoglobin A₁c</th>
<th>Mean hemoglobin A₁c reduction¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pi-Sunyer³⁰⁷</td>
<td>354</td>
<td>50 mg daily, 50 mg twice daily, 100 mg daily</td>
<td>Placebo</td>
<td>Diet/exercise</td>
<td>24 weeks</td>
<td>8.4%</td>
<td>50 mg daily: 0.5% 50 mg twice daily: 0.7% 100 mg daily: 0.9%</td>
</tr>
<tr>
<td>Dejager¹⁰⁸</td>
<td>632</td>
<td>50 mg daily, 50 mg twice daily, 100 mg daily</td>
<td>Placebo</td>
<td>Diet/exercise</td>
<td>24 weeks</td>
<td>8.5%</td>
<td>50 mg daily: 0.8% 50 mg twice daily: 0.7% 100 mg daily: 0.9%</td>
</tr>
<tr>
<td>Scherbaum¹⁰⁹</td>
<td>306</td>
<td>50 mg daily</td>
<td>Placebo</td>
<td>Diet/exercise</td>
<td>52 weeks</td>
<td>6.7%</td>
<td>0.3% 1 year: 0.3% 2 years: 0.5%</td>
</tr>
<tr>
<td>Scherbaum³³</td>
<td>131</td>
<td>50 mg daily</td>
<td>Placebo</td>
<td>Diet/exercise</td>
<td>104 weeks (52 weeks then 4-week wash-out, then 52 weeks)</td>
<td>6.6%</td>
<td></td>
</tr>
<tr>
<td>Ristic³⁸</td>
<td>279</td>
<td>25, 50, 100 mg daily, 25 mg twice daily</td>
<td>Placebo</td>
<td>Diet/exercise</td>
<td>12 weeks</td>
<td>7.7%</td>
<td>50 mg daily: 0.56% 100 mg daily: 0.53% Other groups were not statistically significantly different from placebo</td>
</tr>
<tr>
<td>Schweizer³⁸⁴</td>
<td>780</td>
<td>100 mg daily</td>
<td>Metformin</td>
<td>Diet/exercise</td>
<td>52 weeks</td>
<td>8.7%</td>
<td>Vildagliptin: 1.0% Metformin: 1.4% Vildagliptin effect did not reach statistical noninferiority</td>
</tr>
<tr>
<td>Goke³⁸³</td>
<td>463</td>
<td>100 mg daily</td>
<td>Metformin</td>
<td>Diet/exercise</td>
<td>104 weeks (52 week extension of previous study³⁶)</td>
<td>Vildagliptin: 8.4% Metformin: 8.8%</td>
<td>Vildagliptin: 1.0% Metformin: 1.5% Vildagliptin effect did not reach statistical noninferiority</td>
</tr>
<tr>
<td>Rosenstock³⁶⁶</td>
<td>786</td>
<td>50 mg twice daily</td>
<td>Rosiglitazone</td>
<td>Diet/exercise</td>
<td>24 weeks</td>
<td>8.7%</td>
<td>1.1% – noninferior to rosiglitazone</td>
</tr>
<tr>
<td>Rosenstock³⁶⁵</td>
<td>607</td>
<td>100 mg daily</td>
<td>Pioglitazone 30 mg vs vildagliptin + pioglitazone combination (100/30 mg daily or 50/15 mg daily)</td>
<td>Diet/exercise</td>
<td>24 weeks</td>
<td>8.7%</td>
<td>Vildagliptin: 1.1% Pioglitazone: 1.4% 100/30 mg daily: 1.9% 50/15 mg daily: 1.7%</td>
</tr>
<tr>
<td>Pan³⁷</td>
<td>661</td>
<td>50 mg twice daily</td>
<td>Acarbose</td>
<td>Diet/exercise</td>
<td>24 weeks</td>
<td>8.6%</td>
<td>Vildagliptin: 1.4% Acarbose: 1.3%</td>
</tr>
<tr>
<td>Bosi³⁹</td>
<td>484</td>
<td>50 or 100 mg daily</td>
<td>Placebo</td>
<td>Metformin</td>
<td>24 weeks</td>
<td>8.4%</td>
<td>50 mg daily: 0.7% 100 mg daily: 1.1%</td>
</tr>
<tr>
<td>Ahren³⁰</td>
<td>57</td>
<td>50 mg daily</td>
<td>Placebo</td>
<td>Metformin</td>
<td>52 weeks</td>
<td>7.7%</td>
<td>1.0% 50 mg daily: 0.6% 50 mg twice daily: 0.7%</td>
</tr>
<tr>
<td>Garber³¹</td>
<td>515</td>
<td>50 mg daily or twice daily</td>
<td>Placebo</td>
<td>Glimeperide 4 mg daily</td>
<td>24 weeks</td>
<td>8.5%</td>
<td>50 mg daily: 0.6% 50 mg twice daily: 0.7%</td>
</tr>
<tr>
<td>Study</td>
<td>Participants</td>
<td>Treatment</td>
<td>Comparator</td>
<td>Duration</td>
<td>HbA1c</td>
<td>Notes</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>-----------</td>
<td>------------</td>
<td>----------</td>
<td>-------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>Garber</td>
<td>463</td>
<td>50 or 100 mg daily</td>
<td>Placebo</td>
<td>Pioglitazone</td>
<td>24 weeks</td>
<td>8.7%</td>
<td>50 mg daily: 0.8% 100 mg daily: 1.0%</td>
</tr>
<tr>
<td>Fonseca</td>
<td>296</td>
<td>50 mg twice daily</td>
<td>Placebo</td>
<td>Insulin</td>
<td>24 weeks</td>
<td>8.4%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Bolli</td>
<td>576</td>
<td>50 mg twice daily</td>
<td>Pioglitazone</td>
<td>Metformin</td>
<td>24 weeks</td>
<td>8.4%</td>
<td>0.9% from baseline – noninferior to pioglitazone</td>
</tr>
<tr>
<td><strong>Saxagliptin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosenstock</td>
<td>338</td>
<td>2.5, 5, 10, 20 or 40 mg daily</td>
<td>Placebo</td>
<td>Diet/exercise</td>
<td>12 weeks</td>
<td>7.9%</td>
<td>0.45%–0.63%</td>
</tr>
<tr>
<td>Rosenstock</td>
<td>85</td>
<td>100 mg daily</td>
<td>Placebo</td>
<td>Diet/exercise</td>
<td>6 weeks</td>
<td>7.8%</td>
<td>Main treatment cohort: 2.5 mg daily: 0.62% 5 mg daily: 0.65% 10 mg daily: 0.73% Open-label cohort: 1.87%</td>
</tr>
<tr>
<td>Rosenstock</td>
<td>401</td>
<td>2.5, 5, or 10 mg daily</td>
<td>Placebo</td>
<td>Diet/exercise</td>
<td>24 weeks</td>
<td>9.4%–9.6%</td>
<td></td>
</tr>
<tr>
<td>DeFronzo</td>
<td>743</td>
<td>2.5, 5, or 10 mg daily</td>
<td>Placebo</td>
<td>Metformin</td>
<td>24 weeks</td>
<td>9.4%–9.6%</td>
<td></td>
</tr>
<tr>
<td>Jadzinsky</td>
<td>1306</td>
<td>10 mg daily</td>
<td>Metformin or metformin + saxagliptin 5 mg or 10 mg daily</td>
<td>Diet/exercise</td>
<td>24 weeks</td>
<td>2.5 mg daily: 0.54% 5 mg daily: 0.64% Glyburide up titration: +0.08%</td>
<td></td>
</tr>
<tr>
<td>Chacra</td>
<td>768</td>
<td>2.5 or 5 mg daily</td>
<td>Glyburide uptitrated to 15 mg daily</td>
<td>Glyburide 10 mg maximum</td>
<td>24 weeks</td>
<td>8.4%–8.5%</td>
<td></td>
</tr>
<tr>
<td><strong>Alogliptin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nauck</td>
<td>527</td>
<td>12.5 or 25 mg daily</td>
<td>Placebo</td>
<td>Metformin</td>
<td>26 weeks</td>
<td>7.9%–8.0%</td>
<td></td>
</tr>
<tr>
<td>Pratley</td>
<td>500</td>
<td>12.5 or 25 mg daily</td>
<td>Placebo</td>
<td>Glyburide</td>
<td>26 weeks</td>
<td>8.1%</td>
<td></td>
</tr>
<tr>
<td>Rosenstock</td>
<td>390</td>
<td>12.5 or 25 mg daily</td>
<td>Placebo</td>
<td>Insulin with or without metformin</td>
<td>26 weeks</td>
<td>9.3%</td>
<td></td>
</tr>
</tbody>
</table>

*Placebo-subtracted, statistically significant hemoglobin A1c value unless stated otherwise.

**Abbreviations:** M2000/S100, metformin 2000 mg, sitagliptin 100 mg; M1000/S100, metformin 1000 mg, sitagliptin 100 mg; M2000, metformin 2000 mg; M1000, metformin 1000 mg; S100, sitagliptin 100 mg.
glucose-lowering effects of linagliptin 2.5 mg twice daily as add on to metformin, and the second will examine its efficacy as add-on therapy to insulin.

**Effects of therapies on beta cell function, alpha cell function, and peripheral glucose metabolism**

One attractive feature of DPP-4 inhibitors is the potential beneficial effect they exert on pancreatic beta cells. In efficacy trials of sitagliptin, vildagliptin, and saxagliptin, investigators have consistently reported improvements in markers of beta cell function, including HOMA-β, insulin:proinsulin ratio, glucose to insulin concentration-time curve (AUC) ratio, and the insulinogenic index.2,32,52,55,59,61,62,70–72,81–85 Islet function has also been shown to improve with administration of vildagliptin in patients with impaired glucose tolerance that have not yet progressed to type 2 diabetes. However, it has not yet been shown that this therapy delays progression of the disease in these patients. Fasting insulin levels also increase with DPP-4 inhibition, further supporting an improvement in beta cell function. A small study conducted by D’Alessio et al examined fasting insulin production in patients with well-controlled type 2 diabetes on metformin or dietary therapy, given add-on treatment with vildagliptin. The study described DPP-4 induced improvement in fasting islet cell function even in patients with well-controlled diabetes. In rodent models, studies of DPP-4 inhibitors have demonstrated that exposure to these agents inhibits apoptosis, augments beta cell replication and increases beta cell mass. However, rodents have high rates of beta cell turnover, which may allow for a very robust physiologic response to DPP-4 inhibition; it is unclear whether the findings of beta cell proliferation and growth can be translated to humans.

Unlike the other DPP-4 inhibitors, alogliptin studies have not as clearly supported an improvement in beta cell function other than that demonstrated by glucose lowering. Although db/db mice treated with alogliptin showed improvement in markers of beta cell function, studies in humans have not documented improvement in HOMA-β or proinsulin:insulin ratio.89,76,77

In addition to their effects on the beta cells, DPP-4 inhibitors appear to have effects on the alpha cells as well. Alpha cells are dysfunctional in patients with type 2 diabetes, resulting in unregulated glucagon production. As a result, hepatic glucose production is not suppressed during times of hyperglycemia. Incretin hormones enhance the sensitivity of alpha cells to glucose. Increases in incretin hormone levels via DPP-4 inhibition with both vildagliptin and sitagliptin have been shown to have this physiologic effect, demonstrated by appropriately decreased post-prandial glucagon levels.

There is evidence to suggest that vildagliptin may also improve peripheral glucose utilization, as assessed by Azuma et al with an insulin infusion study. The authors speculate that there may be a direct effect of GLP-1 or GIP on glucose uptake. Conversely, Hanefield et al examined measures of insulin resistance, specifically the quantitative insulin sensitivity check index (QUICKI) and HOMA-insulin resistance, in a study of sitagliptin; there was no difference from placebo in these measures. Further data are needed to establish whether there is, in fact, an incretin effect at peripheral tissues or whether this may be a unique effect of vildagliptin.

**Nonglycemic effects, including cardiovascular effects**

In addition to the effects on glucose metabolism, incretin hormones may also affect lipids, blood pressure, and cardiovascular health. Endogenous GLP-1 has been shown to slow gastric emptying, increase satiety, and reduce food intake. Despite the increase in endogenous GLP-1 levels with administration of DPP-4 inhibitors, these medications have not been shown to exert similar effects. When compared directly with exenatide, a GLP-1 agonist, patients taking exenatide had reduced caloric intake and slowed gastric emptying in response to that drug, while patients taking sitagliptin did not. GLP-1 agonist therapy has also been associated with mild systolic blood pressure reduction of 2 to 6 mmHg; this effect has not yet been demonstrated with DPP-4 inhibitors. Finally, therapy with GLP-1 agonists is associated with weight loss, while the DPP-4 inhibitors are generally weight neutral.

Vildagliptin and sitagliptin have been examined for lipid-lowering effects, particularly for changes in post-prandial triglyceride levels. In an efficacy study comparing vildagliptin with rosiglitazone, patients treated with vildagliptin 50 mg twice daily experienced reductions in triglycerides (9%), total cholesterol (14%), low-density lipoprotein (LDL) cholesterol (16%), and non-high-density lipoprotein (HDL) cholesterol (16%); all were statistically greater reductions than those seen with rosiglitazone. Vildagliptin therapy also increased HDL cholesterol, although it was not to the same extent as rosiglitazone, 4% versus 9% respectively. Vildagliptin therapy has been examined specifically for reduction of postprandial triglyceride-rich lipoproteins in patients.
with type 2 diabetes; reductions in both apolipoprotein B48 and cholesterol components were reported. Modest improvements in HDL cholesterol, about 4%, and reductions in triglyceride levels of 9% have also been reported with sitagliptin therapy. Total, LDL, and non-HDL cholesterol were not improved. Reductions in lipid levels appear to be independent from the glucose-lowering effects of these drugs, as sulfonylureas and thiazolidinediones with similar glucose-lowering efficacy, have not shown the same lipid effects in head-to-head comparisons.

**Safety and tolerability**

**Side effects**

There have been numerous individual trials and 3 large meta-analyses to examine the safety and tolerability of the DPP-4 inhibitors as a class. The analyses have shown that these medications are generally well-tolerated in the short term. With respect to hypoglycemia, the DPP-4 inhibitors have performed well. Their use has not been commonly associated with any degree of hypoglycemia. Although a few individual trials have found an increase in mild hypoglycemia when DPP-4 inhibitors are combined with other antidiabetic medications, 2 meta-analyses have shown that there has been no significant difference from placebo, even when DPP-4 inhibitors are combined with sulfonylureas or insulin. Monami et al examined unpublished data and described five cases of severe hypoglycemia in sitagliptin monotherapy; these cases were fewer than those in sulfonylurea comparator groups and were not discussed in the published literature. Another feature in favor of the use of DPP-4 medications is that they have not been associated with weight gain. Meta-analyses of sitagliptin, vildagliptin, alogliptin, and saxagliptin concluded that there has been no clinically significant effect on BMI in placebo-controlled trials.

Reported side effects have generally been mild, such as increased rate of headaches with vildagliptin and increased rates of upper respiratory tract infections with sitagliptin. Increased rates of other mild infections, such as urinary tract infection, have been reported in individual trials and were associated with use of sitagliptin in a 2009 Cochrane review. However, a more recent meta-analysis did not confirm this association. In the postmarketing period, the use of sitagliptin has been associated with cases of mild to severe hypersensitivity reactions, including anaphylaxis, angioedema, and exfoliative skin conditions. These have occurred in the first few months of therapy; in one case, after the first dose. Continued use of or re-exposure to sitagliptin is contraindicated in patients who have experienced hypersensitivity reactions. Vildagliptin has been associated with rare cases of hepatic dysfunction, and should not be used in patients with pre-existing moderate to severe hepatic failure. Vildagliptin was also associated with a skin blistering condition in nonclinical toxicology studies with primates. This has not been reported in human studies at recommended therapeutic dosages, and is not reported in post-marketing data. More studies are needed to examine the potential immunomodulatory effects of vildagliptin and determine whether they are greater than that seen with use of other agents in this class.

The US Food and Drug Administration (FDA) recently called attention to a number of cases of acute pancreatitis, which were temporally associated with the initiation of sitagliptin. This announcement raises concern given that a similar association had been observed with the GLP-1 agonist exenatide. The classes of drugs that utilize the incretin pathway are known to have direct effects on the structure of the pancreas in rodent models, suggesting the possibility for a causal relationship with pancreatitis, although the mechanism is unclear. In one rodent study, use of GLP-1 receptor agonists was associated with increase in pancreatitis-associated gene expression but not with pancreatitis. Matveyenko et al conducted a rodent model study to examine the effects on the pancreas of metformin and sitagliptin in combination. The two drugs appeared to have synergistic effect to preserve beta-cell mass and function, but use of sitagliptin was associated with increased pancreatic ductal turnover, ductal metaplasia, and, in one rat, pancreatitis. These findings do raise concern; however, this information has yet to be confirmed in humans. Human data exist in the form of a retrospective analysis of around 88,000 patient hospitalization records, which examined rates of admission for acute pancreatitis in patients using incretin-based therapies (exenatide and sitagliptin) compared to matched groups of patients using metformin and glyburide. They found that hospitalizations for acute pancreatitis within 1 year of initiation of the respective drugs were similar for the four medications, with a rate of 0.13% per year of patients on exenatide and 0.12% per year for patients on sitagliptin. Given that the human data at this point are limited to postmarketing reports and retrospective data analysis, the true relationship of pancreatitis to incretin-based therapy remains unknown. Given the baseline rate of pancreatitis in people with diabetes, it is currently difficult to know if reports of pancreatitis in people on incretin therapies are truly attributable to drug usage. Data accumulated from large, long-term trials with sitagliptin and other DPP-4 inhibitors may provide much needed information.
regarding this relationship. For now, the FDA recommends that physicians warn patients about the potential risk as well as the symptoms of pancreatitis, and discontinue the drugs if symptoms or signs of pancreatitis develop.99

The FDA now requires that therapies approved to treat type 2 diabetes should provide data to demonstrate that the therapy will not result in an unacceptable increase in cardiovascular risk.104 Saxagliptin was the first drug approved following establishment of this guideline; its use was not associated with an increased risk of cardiovascular events in pooled data from eight pre-marketing clinical trials.105 However, the number of cardiovascular events occurring during these trials was inadequate to confidently exclude a differential effect; thus a long-term cardiovascular outcomes trial of this medication will be required. Although analysis of data from early studies of sitagliptin and vildagliptin found that mortality and cardiovascular event rates were similar between these drugs and comparators, no individual trial with these agents was powered to examine this outcome.51 A long-term cardiovascular outcomes trial of sitagliptin therapy in individuals at high risk for such complications began enrollment in December of 2008. The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) is an international trial of 14,000 individuals with diabetes and cardiovascular disease which will assess the impact of sitagliptin therapy on events including cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina.106

**Conclusion**

Therapy for type 2 diabetes is complex; many patients require multiple medications to reach optimal glycemic targets. As outlined in the ADA/EASD algorithm for diabetes medications, there are multiple potential combinations of medications for any individual; the provider must consider co-morbidities and patient preferences when making these decisions. Although the DPP-4 inhibitor class is not yet well-studied enough to have been included in the algorithm, studies suggest that these drugs’ mechanisms of action complement those of traditionally used diabetes medications. The DPP-4 inhibitors have been criticized for having lower glucose-lowering efficacy than other available therapies, particularly insulin.4 However, the active comparator trials data suggest that they can be as effective as more traditionally prescribed therapies. Furthermore, they are generally well tolerated, do not cause weight gain, and may provide some beta cell protection. Unlike many traditional medications, these drugs rarely cause hypoglycemia and some agents have no major contraindications to use. These attributes make this class of drugs attractive for use in the elderly, for those who have multiple co-morbidities precluding the use of other medications, and for those in whom insulin therapy proves difficult.

Data on these drugs continue to be accrued, and it is likely that the safety concerns related to the immune system and pancreatitis will be prospectively and more comprehensively addressed. Long-term trials are also needed to determine if preliminary data suggesting beta cell preservation will be borne out in clinical practice. Further investigations are also needed to examine long-term effects of these agents on cardiovascular outcomes and mortality.

**Acknowledgments**

Drs Cox and Rowell are supported by NIH Training Grant T32-DK007102-31 at Duke University Medical Center.

**Disclosures**

Dr Green is a member of the Takeda and Merck speakers’ bureaus. She also performs research for which Merck is the sponsor.

**References**


